GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » 14-Day RSI

Cibus (CBUS) 14-Day RSI : 55.75 (As of May. 18, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Cibus 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-18), Cibus's 14-Day RSI is 55.75.

The industry rank for Cibus's 14-Day RSI or its related term are showing as below:

CBUS's 14-Day RSI is ranked worse than
74.59% of 1574 companies
in the Biotechnology industry
Industry Median: 48.37 vs CBUS: 55.75

Competitive Comparison of Cibus's 14-Day RSI

For the Biotechnology subindustry, Cibus's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cibus's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cibus's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Cibus's 14-Day RSI falls into.



Cibus  (NAS:CBUS) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cibus  (NAS:CBUS) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Cibus 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Cibus's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cibus (CBUS) Business Description

Traded in Other Exchanges
N/A
Address
6455 Nancy Ridge Drive, San Diego, CA, USA, 92121
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.
Executives
Rory B Riggs director, officer: Chief Executive Officer 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr. director 1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn 10 percent owner C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante director SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn director VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann director 21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker director 13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King officer: Chief Financial Officer 750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William officer: See Remarks 13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham director, officer: See Remarks 6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill director C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr director, officer: President and CEO 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak officer: Chief Financial Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter officer: Chief Business Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas officer: Chief Science Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113